Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011–2018 DOI Creative Commons

Maximino Acevedo-Fernández,

Renata Ochoa Precoma,

Leonardo M. Porchia

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0318413 - e0318413

Published: Feb. 3, 2025

Background Visceral obesity (VATob) increases the risk for many diseases. Central has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, aim was to evaluate association between VATob and use. Methods Data collected from NHANES dataset (2011–2018). adipose tissue measured using dual x-ray absorptiometry, defined as ≥100 cm 2 . Prescription use RXQ_RX files classified according Vademecum. Association determined logistic regression reported odds ratios (ORs) 95% confidence intervals (95%CIs). Results 10,952 participants (weighted: 121,090,702) were included, in which 41.8% 52.0% them had ≥1 prescription. Overall, demonstrated rate when compared non-VATob (52.0% versus 36.7%, p<0.001), specifically metabolic (4.5-fold increase), cardiovascular (3.9-fold gastrointestinal (2.5-fold hematopoietic agents (2.3-fold increase). This increased overall (OR = 1.9, 95%CI: 1.7–2.1, p<0.001). Similar results observed agents. However, stratified by BMI, normal weight 10.4; 6.5–16.6 & OR 7.0; 4.4–11.1, p<0.001) greater than overweight 4.1; 3.0–5.6 3.4; 2.5–4.7, or obese 3.5; 2.3–5.3 2.5–4.9, Conclusion use, particularly higher participants.

Language: Английский

Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011–2018 DOI Creative Commons

Maximino Acevedo-Fernández,

Renata Ochoa Precoma,

Leonardo M. Porchia

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0318413 - e0318413

Published: Feb. 3, 2025

Background Visceral obesity (VATob) increases the risk for many diseases. Central has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, aim was to evaluate association between VATob and use. Methods Data collected from NHANES dataset (2011–2018). adipose tissue measured using dual x-ray absorptiometry, defined as ≥100 cm 2 . Prescription use RXQ_RX files classified according Vademecum. Association determined logistic regression reported odds ratios (ORs) 95% confidence intervals (95%CIs). Results 10,952 participants (weighted: 121,090,702) were included, in which 41.8% 52.0% them had ≥1 prescription. Overall, demonstrated rate when compared non-VATob (52.0% versus 36.7%, p<0.001), specifically metabolic (4.5-fold increase), cardiovascular (3.9-fold gastrointestinal (2.5-fold hematopoietic agents (2.3-fold increase). This increased overall (OR = 1.9, 95%CI: 1.7–2.1, p<0.001). Similar results observed agents. However, stratified by BMI, normal weight 10.4; 6.5–16.6 & OR 7.0; 4.4–11.1, p<0.001) greater than overweight 4.1; 3.0–5.6 3.4; 2.5–4.7, or obese 3.5; 2.3–5.3 2.5–4.9, Conclusion use, particularly higher participants.

Language: Английский

Citations

0